Compare WLKP & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WLKP | STOK |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 652.0M | 1.9B |
| IPO Year | 2014 | 2019 |
| Metric | WLKP | STOK |
|---|---|---|
| Price | $19.83 | $32.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $31.00 |
| AVG Volume (30 Days) | 64.9K | ★ 930.2K |
| Earning Date | 10-30-2025 | 11-04-2025 |
| Dividend Yield | ★ 9.54% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.39 | 0.68 |
| Revenue | ★ $1,133,706,000.00 | $205,632,000.00 |
| Revenue This Year | $3.88 | $430.24 |
| Revenue Next Year | $12.71 | N/A |
| P/E Ratio | ★ $14.17 | $47.31 |
| Revenue Growth | N/A | ★ 1128.17 |
| 52 Week Low | $17.75 | $5.35 |
| 52 Week High | $25.04 | $38.69 |
| Indicator | WLKP | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 63.97 | 58.66 |
| Support Level | $18.88 | $30.17 |
| Resistance Level | $19.19 | $35.40 |
| Average True Range (ATR) | 0.38 | 2.13 |
| MACD | 0.17 | 0.31 |
| Stochastic Oscillator | 86.29 | 61.10 |
Westlake Chemical Partners LP is a part of the chemical industry in the United States. Its operations are conducted through OpCo, it acquires and develops ethylene production facilities, which convert ethane into ethylene. OpCo sells ethylene and its co-products such as propylene, crude butadiene, pyrolysis gasoline, and hydrogen to Westlake and other customers located in the United States. Its assets include three ethylene production facilities in Calvert City, Kentucky, and Lake Charles, Louisiana.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.